Navigation Links
Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals' Lorcaserin Achieved Statistically Significant Weight Loss
Date:5/26/2011

rcaserin NDA, including related plans and activities; the Eisai collaboration and potential activities thereunder; lorcaserin's patent coverage; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's research and development programs, including for lorcaserin, may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena submits such response or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
3. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
4. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
5. KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
6. Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
7. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
8. Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
9. EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting
10. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
11. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Headquartered in ... a diversified company comprised of several specialized partners focused ... and the proven expertise of its team of professionals ... WholeHealth Products, line of more than 10 professional diagnostic ... its more than 8 retail consumer tests is proud ...
(Date:9/30/2014)... , Sept. 30, 2014  Synapse Biomedical Inc. ( ... enrollment of the post-approval study of its NeuRx ... needed to meet the FDA enrollment requirement was ... of schedule.  The NeuRx DPS®, which is the ... for ALS patients, is a humanitarian device that ...
(Date:9/30/2014)... 30, 2014 Summary This report ... pharmaceutical companies regarding their Information & Communications Technology ... companies currently allocate their ICT budgets across the ... IT services, communications, and consulting. Key ... companies highlights that X% of respondents anticipate an ...
Breaking Medicine Technology:WholeHealth Products Announces The Discovery Of The "Autism And Fragile X" Microwell And Rapid Diagnostic Test 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3ICT investment trends in pharmaceuticals - Enterprise ICT spending patterns through to the end of 2015 2ICT investment trends in pharmaceuticals - Enterprise ICT spending patterns through to the end of 2015 3
... 7, 2011 Healthmark Industries was honored with two ... Healthcare Central Service Personnel (MSHCSP). At last ... presented with the Lifetime Honorary Achievement Award for his ... The same night Healthmark was also awarded ...
... Among the first healthcare providers to have money in ... health record (EHR) incentive program -- are two Texas ... Canadian, Texas. Both Stamford and Hemphill quickly ... meaningful use to be among the initial 37 hospitals ...
Cached Medicine Technology:Two Texas Hospitals Leverage Prognosis EHR to Meet Meaningful Use Requirements and Receive ARRA Incentive Funds 2
(Date:9/30/2014)... Hospice & Palliative Care of ... gala, honoring three outstanding individuals for their commitment ... provide extraordinary and dignified comfort, care and compassion ... life-limiting illness. , The event was held at ... recognized William (Bill) J. McGuinness, Director of Tiffany ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Dr. Karl ... knee pain program of care that is dramatically ... , His clinic—Johnson Chiropractic Neurology & Nutrition—applies a proprietary, ... knee. It also addresses sources of inflammation, neurology of ... the “neurokinetic chain” from the brain to the spine, ...
(Date:9/30/2014)... WASHINGTON (Sept. 30, 2014) Levothyroxine is considered the ... and a new review of therapies for the condition ... not altered that assessment, say a team of investigators.,1Their ... journal Thyroid , finds insufficient consistent data exist ... whether generic, or sold under various trade names, such ...
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 Healthcare ... at the National Association of Health Advocacy Consultants (#NAHAC) ... Healthcare Advocacy” (#NAHAC14) to be held October 30th - ... its debut at NAHAC14: Standards and Best Practices for ... grows into a profession, advocates have needed a set ...
(Date:9/30/2014)... September 30, 2014 Market Research ... is a professional and in-depth market survey on ... reviews the basic information of Cialis including its ... explores global and China’s top manufacturers of Cialis ... market share etc. , The report further analyzes ...
Breaking Medicine News(10 mins):Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4
... , TUESDAY, March 1 (HealthDay News) -- A ... hospitals for sepsis -- a potentially life-threatening bacterial infection in ... those treated at other hospitals. Researchers analyzed data from ... sepsis between June 2004 and June 2006. In total, there ...
... over time been able to show that medicine designed ... serious diseases such as cancer. However, now research also ... part in the drug delivery process. "Researchers ... of viruses. The nanoparticles are effective for drug delivery ...
... ATLANTA March 1, 2011 A new report from ... the 141,000 cases and 49,000 deaths from colorectal cancer ... prevented by increasing the use of established screening tests ... The report, Colorectal Cancer Facts & Figures 2011-2013, released ...
... Invasive plant species have long had a reputation as being ... Stan Harpole, assistant professor of ecology, evolution and organismal biology ... of more than 70 researchers working at 65 sites worldwide ... it is true that problematic invasive species often spread widely ...
... Los Angeles, CA (February 28, 2011) Eating more tomatoes ... the risk of conditions such as cancer, osteoporosis and ... American Journal of Lifestyle Medicine , (published by SAGE). ... tomatoes and tomato products than any others. Researchers Britt ...
... , TUESDAY, March 1 (HealthDay News) -- For ... to relieve symptoms and result in major improvements in ... Up to 20 percent of women in their childbearing ... Not all fibroids cause symptoms, but some patients experience ...
Cached Medicine News:Health News:Hospital Spending Doesn't Affect Sepsis Survival Rates 2Health News:Research provides new findings on drug delivery with nanoparticles 2Health News:New report says large proportion of colorectal cancer deaths could be prevented 2Health News:Global ISU study: Invasive species widespread, but not more than at home range 2Health News:Health benefits of eating tomatoes emerge 2Health News:Uterine Fibroid Treatments Seem to Boost Quality of Life 2
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: